1. Home
  2. IVA vs SANG Comparison

IVA vs SANG Comparison

Compare IVA & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • SANG
  • Stock Information
  • Founded
  • IVA 2011
  • SANG 1984
  • Country
  • IVA France
  • SANG Canada
  • Employees
  • IVA N/A
  • SANG N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • SANG Computer Software: Programming Data Processing
  • Sector
  • IVA Health Care
  • SANG Technology
  • Exchange
  • IVA Nasdaq
  • SANG Nasdaq
  • Market Cap
  • IVA 359.6M
  • SANG 213.1M
  • IPO Year
  • IVA 2020
  • SANG 2021
  • Fundamental
  • Price
  • IVA $3.48
  • SANG $5.99
  • Analyst Decision
  • IVA Strong Buy
  • SANG
  • Analyst Count
  • IVA 4
  • SANG 0
  • Target Price
  • IVA $10.50
  • SANG N/A
  • AVG Volume (30 Days)
  • IVA 15.6K
  • SANG 2.5K
  • Earning Date
  • IVA 03-26-2025
  • SANG 05-08-2025
  • Dividend Yield
  • IVA N/A
  • SANG N/A
  • EPS Growth
  • IVA N/A
  • SANG N/A
  • EPS
  • IVA N/A
  • SANG N/A
  • Revenue
  • IVA $14,591,573.00
  • SANG $238,264,000.00
  • Revenue This Year
  • IVA $15.38
  • SANG N/A
  • Revenue Next Year
  • IVA $24.22
  • SANG $2.91
  • P/E Ratio
  • IVA N/A
  • SANG N/A
  • Revenue Growth
  • IVA N/A
  • SANG N/A
  • 52 Week Low
  • IVA $1.53
  • SANG $4.08
  • 52 Week High
  • IVA $4.05
  • SANG $7.99
  • Technical
  • Relative Strength Index (RSI)
  • IVA 52.61
  • SANG 51.32
  • Support Level
  • IVA $3.13
  • SANG $6.23
  • Resistance Level
  • IVA $3.48
  • SANG $6.49
  • Average True Range (ATR)
  • IVA 0.24
  • SANG 0.09
  • MACD
  • IVA 0.03
  • SANG -0.00
  • Stochastic Oscillator
  • IVA 51.90
  • SANG 43.18

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

Share on Social Networks: